Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan versus epirubicin DEB-TACE for unresectable hepatocellular carcinoma
ChiCTR1800018964Phase 2Not yet recruiting
- Sponsor
- Shaanxi Cancer Hospital
- Start
- Dec 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan and epirubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Shaanxi Cancer Hospital. Primary endpoint: Time to progression. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
irinotecanepirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800018964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018964.